{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:52:02Z","timestamp":1790776322106,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.neurobiolaging.2017.08.006","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:01:15Z","timestamp":1502323275000},"page":"156-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["MultiTEP platform\u2013based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency"],"prefix":"10.1016","volume":"59","author":[{"given":"Hayk","family":"Davtyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zagorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Petrushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Kazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie R.S.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Petrosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Blurton-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Cribbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Agadjanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-0616","authenticated-orcid":false,"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12026-008-8076-3","article-title":"DNA vaccines: developing new strategies to enhance immune responses","volume":"42","author":"Abdulhaqq","year":"2008","journal-title":"Immunol. Res."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib2","first-page":"175","article-title":"DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1","volume":"226","author":"Agadjanyan","year":"1998","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib3","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib4","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","article-title":"Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in\u00a0vivo by immunotherapy","volume":"22","author":"Bacskai","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib5","doi-asserted-by":"crossref","first-page":"e26609","DOI":"10.1371\/journal.pone.0026609","article-title":"Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy","volume":"6","author":"Badiola","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1073\/pnas.0436286100","article-title":"Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology","volume":"100","author":"Bard","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib7","doi-asserted-by":"crossref","first-page":"E4274","DOI":"10.1073\/pnas.1416598111","article-title":"alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation","volume":"111","author":"Burre","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid","volume":"15","author":"Cribbs","year":"2003","journal-title":"Int. Immunol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","article-title":"The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates","volume":"10","author":"Davtyan","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib10","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, Safety, and Mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: Prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/1566523214666140522121427","article-title":"BTX AgilePulse(TM) system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine","volume":"14","author":"Davtyan","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jalz.2013.04.505","article-title":"Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques","volume":"10","author":"Evans","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"Suppl 4","key":"10.1016\/j.neurobiolaging.2017.08.006_bib13","first-page":"IV37","article-title":"Does levodopa slow or hasten the rate of progression of Parkinson's disease?","volume":"252","author":"Fahn","year":"2005","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib14","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib15","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0002-9440(10)61119-4","article-title":"Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam","volume":"160","author":"Forman","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nn2058","article-title":"A\u00a0molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides","volume":"11","author":"Gallardo","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib17","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/187152709787847298","article-title":"Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy","volume":"8","author":"Ghochikyan","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib19","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4161\/hv.23875","article-title":"Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits","volume":"9","author":"Ghochikyan","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neulet.2013.12.028","article-title":"Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human alpha-synuclein: feasibility study","volume":"560","author":"Ghochikyan","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuclein","volume":"300","author":"Giasson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1385\/NMM:4:1-2:49","article-title":"Interactions of amyloidogenic proteins","volume":"4","author":"Giasson","year":"2003","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/ncomms2534","article-title":"Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia","volume":"4","author":"Kim","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib24","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0264-410X(98)00177-7","article-title":"Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes","volume":"16","author":"Kim","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib25","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib27","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in\u00a0vivo Does not Require effector function and microglial Engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J.\u00a0Biotechnol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib29","doi-asserted-by":"crossref","first-page":"22376","DOI":"10.1074\/jbc.M700088200","article-title":"Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers","volume":"282","author":"Mamikonyan","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11064-006-9140-9","article-title":"Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease","volume":"31","author":"Mandal","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol. Neurodegener"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-510X(99)00327-5","article-title":"Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease","volume":"174","author":"Marui","year":"2000","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib35","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.expneurol.2008.04.008","article-title":"The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease","volume":"212","author":"McGeer","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib38","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine- a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jneuroim.2008.08.016","article-title":"DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype","volume":"205","author":"Movsesyan","year":"2008","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.expneurol.2007.11.019","article-title":"Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies","volume":"210","author":"Obi","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib41","doi-asserted-by":"crossref","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","article-title":"Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble\/oligomeric A{beta} species in amyloid Precursor protein transgenic mice","volume":"27","author":"Petrushina","year":"2007","journal-title":"J.\u00a0Neurosci."},{"issue":"Pt 6","key":"10.1016\/j.neurobiolaging.2017.08.006_bib42","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/brain\/awv040","article-title":"Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain","volume":"138","author":"Roberts","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jnr.10231","article-title":"Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters","volume":"68","author":"Rockenstein","year":"2002","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib45","doi-asserted-by":"crossref","first-page":"e3135","DOI":"10.1371\/journal.pone.0003135","article-title":"Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases","volume":"3","author":"Tsigelny","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib46","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.cgt.7700973","article-title":"Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in\u00a0vivo electroporation","volume":"13","author":"Ugen","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.neurobiolaging.2017.08.006_bib47","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.cub.2014.08.027","article-title":"alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling","volume":"24","author":"Wang","year":"2014","journal-title":"Curr. Biol."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458017302610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458017302610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T09:11:13Z","timestamp":1545815473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458017302610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":47,"alternative-id":["S0197458017302610"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.08.006","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MultiTEP platform\u2013based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}